[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100441176":3},{"organization":4,"armGroups":7,"interventions":17,"overallOfficials":10,"centralContacts":23,"locations":33,"responsibleParty":163,"collaborators":165,"id":169,"slug":170,"hasResults":171,"nctId":172,"briefTitle":173,"officialTitle":174,"acronym":10,"eligibilityCriteria":175,"healthyVolunteers":171,"sex":176,"minAge":177,"maxAge":10,"enrollmentInfo":178,"targetDuration":10,"studyType":181,"phases":10,"briefSummary":182,"conditions":183,"keywords":10,"overallStatus":36,"whyStopped":10,"lastUpdateSubmitDate":187,"lastUpdatePostDateStruct":188,"startDateStruct":191,"completionDateStruct":193,"leadSponsor":195,"locationsCount":196},{"fullName":5,"class":6},"Children's Hospital of Philadelphia","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Prospective Cohort",null,"Patients with differentiated thyroid cancer for whom oncogene-specific targeted therapy is planned from commercial supply or as part of a separate therapeutic trial",[13],"Procedure: Whole body scan",{"label":15,"type":10,"description":16,"interventionNames":10},"Data Sharing Cohort","Patients with differentiated thyroid cancer enrolled on other oncogene-specific targeted therapy trials who undergo whole body thyroid scan approximately 28 days after beginning targeted therapy and agree to data sharing",[18],{"type":19,"name":20,"description":21,"armGroupLabels":22,"otherNames":10},"PROCEDURE","Whole body scan","Patients will receive oncogene-specific molecularly targeted therapy independently of this protocol either via commercial supply of an FDA approved agent, or as part of a separate therapeutic clinical trial\u002Fcompassionate use protocol\u002Fsingle patient investigational new drug (IND).\n\nDuring screening, patients will undergo a baseline RAI-whole body scan (WBS) to assess RAI-avidity of their tumor per standard of care. Following approximately 28 days of targeted therapy, the WBS will be repeated to determine whether this therapy is associated with an increase in RAI-avidity of their tumor.",[9],[24,29],{"name":25,"role":26,"phone":27,"phoneExt":10,"email":28},"Meghan T Donnelly","CONTACT","2674269343","donnellymt@chop.edu",{"name":30,"role":26,"phone":31,"phoneExt":10,"email":32},"James Robinson","215-590-2053","robinsonj9@chop.edu",[34,55,68,83,98,111,125,135,149],{"facility":35,"status":36,"city":37,"state":38,"zip":39,"country":40,"countryCode":41,"cosmosGeoPoint":42,"geoPoint":47,"contacts":48},"University of California San Francisco","RECRUITING","San Francisco","California","94143","United States","US",{"type":43,"coordinates":44},"Point",[45,46],-122.41942,37.77493,{"lat":46,"lon":45},[49,53],{"name":50,"role":26,"phone":51,"phoneExt":10,"email":52},"Arun Rangaswami, MD","415-298-9434","karina.wong@ucsf.edu",{"name":54,"role":26,"phone":51,"phoneExt":10,"email":52},"Karina Wong",{"facility":56,"status":36,"city":57,"state":58,"zip":59,"country":40,"countryCode":41,"cosmosGeoPoint":60,"geoPoint":64,"contacts":65},"Emory University School of Medicine","Atlanta","Georgia","30322",{"type":43,"coordinates":61},[62,63],-84.38798,33.749,{"lat":63,"lon":62},[66],{"name":67,"role":26,"phone":10,"phoneExt":10,"email":10},"Brianna Patterson, MD",{"facility":69,"status":36,"city":70,"state":71,"zip":72,"country":40,"countryCode":41,"cosmosGeoPoint":73,"geoPoint":77,"contacts":78},"Boston Children's Hospital","Boston","Massachusetts","02115",{"type":43,"coordinates":74},[75,76],-71.05977,42.35843,{"lat":76,"lon":75},[79,81],{"name":80,"role":26,"phone":10,"phoneExt":10,"email":10},"Junne Kamihara, MD",{"name":80,"role":82,"phone":10,"phoneExt":10,"email":10},"PRINCIPAL_INVESTIGATOR",{"facility":5,"status":36,"city":84,"state":85,"zip":86,"country":40,"countryCode":41,"cosmosGeoPoint":87,"geoPoint":91,"contacts":92},"Philadelphia","Pennsylvania","19104",{"type":43,"coordinates":88},[89,90],-75.16362,39.95238,{"lat":90,"lon":89},[93,95,96],{"name":25,"role":26,"phone":94,"phoneExt":10,"email":28},"267-436-9343",{"name":30,"role":26,"phone":31,"phoneExt":10,"email":32},{"name":97,"role":82,"phone":10,"phoneExt":10,"email":10},"Theodore Laetsch, MD",{"facility":99,"status":36,"city":100,"state":101,"zip":102,"country":40,"countryCode":41,"cosmosGeoPoint":103,"geoPoint":107,"contacts":108},"St. Jude Children's Research Hospital","Memphis","Tennessee","38105",{"type":43,"coordinates":104},[105,106],-90.04898,35.14953,{"lat":106,"lon":105},[109],{"name":110,"role":26,"phone":10,"phoneExt":10,"email":10},"Sara Helmig, MD",{"facility":112,"status":36,"city":113,"state":114,"zip":115,"country":40,"countryCode":41,"cosmosGeoPoint":116,"geoPoint":120,"contacts":121},"MD Anderson Cancer Center","Houston","Texas","77030",{"type":43,"coordinates":117},[118,119],-95.36327,29.76328,{"lat":119,"lon":118},[122,124],{"name":123,"role":26,"phone":10,"phoneExt":10,"email":10},"Steven Waguespack, MD",{"name":123,"role":82,"phone":10,"phoneExt":10,"email":10},{"facility":126,"status":36,"city":113,"state":114,"zip":115,"country":40,"countryCode":41,"cosmosGeoPoint":127,"geoPoint":129,"contacts":130},"Texas Children's Hospital",{"type":43,"coordinates":128},[118,119],{"lat":119,"lon":118},[131,133],{"name":132,"role":26,"phone":10,"phoneExt":10,"email":10},"Rajkumar Venkatramani, MD",{"name":134,"role":82,"phone":10,"phoneExt":10,"email":10},"Priya Mahajan, MD",{"facility":136,"status":36,"city":137,"state":138,"zip":139,"country":40,"countryCode":41,"cosmosGeoPoint":140,"geoPoint":144,"contacts":145},"Seattle Children's Hospital","Seattle","Washington","98105",{"type":43,"coordinates":141},[142,143],-122.33207,47.60621,{"lat":143,"lon":142},[146,148],{"name":147,"role":26,"phone":10,"phoneExt":10,"email":10},"Tyler Ketterl, MD, MS",{"name":147,"role":82,"phone":10,"phoneExt":10,"email":10},{"facility":150,"status":36,"city":151,"state":152,"zip":10,"country":153,"countryCode":154,"cosmosGeoPoint":155,"geoPoint":159,"contacts":160},"Children's Hospital Westmead","Sydney","New South Wales","Australia","AU",{"type":43,"coordinates":156},[157,158],151.20732,-33.86785,{"lat":158,"lon":157},[161],{"name":162,"role":26,"phone":10,"phoneExt":10,"email":10},"Paul Benitez-Aguirre, MD",{"type":164,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[166],{"name":167,"class":168},"United States Department of Defense","FED","100441176","targeted-therapy-to-increase-rai-uptake-in-metastatic-dtc-100441176",false,"NCT05024929","Targeted Therapy to Increase RAI Uptake in Metastatic DTC","Targeted Therapy to Increase RAI Uptake in Patients With Metastatic Differentiated Thyroid Cancer","Inclusion Criteria (Prospective Cohort):\n\n1. Patients with a histologic diagnosis of differentiated thyroid cancer\n2. Presence of an neurotrophic tyrosine kinase receptors (NTRK)-fusion, RET-fusion, anaplastic lymphoma kinase (ALK)-fusion, BRAF V600 mutation, BRAF-fusion or other targetable alteration identified in a Clinical Laboratory Improvement Amendments\u002FCollege of American Pathologists (CLIA\u002FCAP) laboratory\n3. Anatomically evaluable disease on chest Computed tomography (CT) meeting oneo f the following criteria (obtained within 180 days of enrollment):\n\n   1. multiple (10 or more) noncalcified solid pulmonary nodules visible on CT and\u002For\n   2. enlarging, discrete pulmonary nodules visible on CT of any number consistent with metastatic disease\n4. Patients for whom systemic therapy with an oncogene-specific kinase inhibitor is planned from commercial supply or as part of a separate therapeutic clinical trial (that does not include data sharing with this protocol)\u002Fcompassionate access protocol\u002Fsingle patient investigational new drug (IND). Such agents include, but are not limited to:\n\n   1. Larotrectinib, entrectinib, selitrectinib, and repotrectinib for NTRK fusions\n   2. Selpercatinib and pralsetinib for RET fusions\n   3. Crizotinib, lorlatinib, repotrectinib, and alectinib for ALK fusions\n   4. Dabrafenib and\u002For trametinib for BRAF V600 mutations\n   5. Oncogene-specific kinase inhibitors other than those specifically delineated above must be approved by the overall study PI prior to enrollment\n\nInclusion Criteria (Data Sharing Cohort):\n\n1\\. Patients enrolled on other oncogene-specific targeted therapy trials who undergo whole body thyroid scan approximately 28 days after beginning targeted therapy and agree to data sharing as part of the consent process for that trial.\n\nExclusion Criteria (All Cohorts):\n\n1. No prior oncogene-specific targeted therapy allowed. However, patients may enroll within 4 weeks of starting oncogene-specific therapy if a pre-therapy WBS is available. Prior therapy with non-oncogene specific multi-thyrosine kinase inhibitors (such as sorafenib, lenvatinib, and\u002For cabozantanib) is allowed.\n2. Females who are pregnant or breastfeeding are excluded due to the potential risks of the RAI used in the WBS to the fetus\u002Fneonate.\n3. Patients who require sedation\u002Fgeneral anesthesia to complete a WBS are excluded.\n4. U.S. Military Personnel are excluded due to the Children's Hospital of Philadelphia (CHOP) Institutional Review Board (IRB) requirements.","ALL","0 Years",{"count":179,"type":180},32,"ESTIMATED","OBSERVATIONAL","Papillary thyroid cancer (PTC) is a common type of differentiated thyroid cancer (DTC) in children and represents the second most common cancer in adolescent females. Recently targeted drugs that block many of the genetic drivers of DTC have become available. While Investigators know that these drugs shrink DTC tumors in many cases, the impact on radioactive iodine (RAI) avidity has not been systematically studied.",[184,185,186],"Papillary Thyroid Cancer","Pediatric Cancer","Differentiated Thyroid Cancer","2025-11-12",{"date":189,"type":190},"2025-11-14","ACTUAL",{"date":192,"type":190},"2021-07-16",{"date":194,"type":180},"2033-02-01",{"name":5,"class":6},9]